C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog.
The success of lung transplantation to a large extent depends on effective protection of the graft from ischemic injury after reperfusion. Although mechanisms have not been clarified, the pathologic findings of ischemic injury after reperfusion are similar to adult respiratory distress syndrome, a condition in which the blood coagulation contact system is activated. This study evaluates the effect of C1-esterase inhibitor (C1-INH), the main inhibitor of the blood coagulation contact system, on short-term lung function in a dog model of orthotopic lung transplantation. Twelve lung transplantations were performed after 24 h of ischemic time. Dogs were randomly assigned to receive either vehicle (Control) or C1-INH. After the lung transplantation in the control group, Pao2 decreased by 84% and both the AaPO2 and the Qs/Qt% increased (340 and 530%, respectively, p < 0.01); these parameters remained unchanged in the C1-INH group. The hypoxemia observed in control animals was associated with decreased blood coagulation contact factors, complement consumption, increased expression of adhesion glycoproteins in leukocytes, and extensive intraalveolar and interstitial neutrophil infiltration. In contrast, C1-INH administration prevented hypoxemia, the decrease in blood coagulation contact factors, the activation of the complement system, the increase in expression of leukocyte adhesion molecules, and inflammatory cell infiltrate. This study has demonstrated that in a dog model of lung transplantation, the administration of C1-INH prevents early pulmonary dysfunction, and it suggests that activation of blood coagulation contact system and complement are important mechanisms causing ischemic injury after reperfusion.
Salvatierra
A
A
Servicio de Cirugía Torácica, Hospital Universitario Reina Sofía, Universidad de Córdoba, Spain.
Velasco
F
F
Rodriguez
M
M
Alvarez
A
A
Lopez-Pedrera
R
R
Ramirez
R
R
Carracedo
J
J
Lopez-Rubio
F
F
Lopez-Pujol
J
J
Guerrero
R
R
D000818:Animals; D003174:Complement C1 Inactivator Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D006439:Hemodynamics; D000860:Hypoxia / Q000209:etiology / Q000517:prevention & control; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008171:Lung Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D016040:Lung Transplantation / Q000502:physiology; D011183:Postoperative Complications / Q000503:physiopathology / Q000517:prevention & control*; D011659:Pulmonary Gas Exchange; D015427:Reperfusion Injury / Q000517:prevention & control*
D003174:Complement C1 Inactivator Proteins